NASDAQ NMS - GLOBAL MARKET · IFRX
-4.17% · -$0.0900 · Vol 544.2K
Live · updated 14:11:03 ET
InflaRx NV

InflaRx NV

Biotechnology
$2.07
+ Add to watchlist
Card

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is IFRX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About InflaRx NV
Biotechnology
Listed since
2017
Employees
65
Country
DE

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.17
Day high
$2.25
Day low
$2.05
Previous close
$2.16
52W high
$2.33
-11.16% from high
52W low
$1.60
64% of range
Market cap
$318.2M
EPS
$-0.4712
Shares out
147.3M
Volume
544.2K
VWAP
$2.10
Price history computed in-house
1W
-6.76%
1M
+27.78%
SMA 50 $1.94 · above
SMA 200 $1.94 · above
52W position 64%
Veridion warehouse edge

Warehouse intelligence for IFRX.

Veridion Score
73
0: 471: 392: 913: 504: 795: Not reported
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

IFRX insider activity

InflaRx NV

Score
Coverage building
Pressure
Mixed
Filings
0
Buys / sells
0 / 0
Net value
Not disclosed
Insiders
0
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Mixed: Not disclosed across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Coverage building

The current Form 4 feed did not return value-bearing open-market rows for IFRX.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

IFRX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for IFRX in this window.
Lobbying spend

IFRX lobbying filings, year to date.

Registered lobbying filings matched to InflaRx NV.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for IFRX in this window.
Latest news · IFRX
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for IFRX.
Options
Sovereign unlock shows live options positioning for IFRX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.